Iida Satofumi, Kinoshita Haruki, Kawanishi Takehiko, Hayashi Masahiro
Clinical Pharmacology Department, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
Eur J Drug Metab Pharmacokinet. 2009 Apr-Jun;34(2):107-15. doi: 10.1007/BF03191159.
By using a population pharmacokinetic analysis method, we predicted the efficacy of Ceftriaxone (CTRX) based on the pharmacokinetics of CTRX in Japanese adults and the sensitivity of infective organisms to CTRX in 2004. In addition, we clarified the difference in efficacy between once-a-day administration and twice-a-day administration.
The population pharmacokinetic analysis was based on the serum concentrations of CTRX already published by NONMEM. The possible effect of body weight and age on the pharmacokinetics of CTRX was examined using a model which incorporated the change of a specific protein-binding ratio of CTRX. A Monte Carlo simulation was conducted based on the population pharmacokinetic parameters obtained by this analysis, and thereby the time above MIC (TAM) was determined from the MIC values of CTRX administered once at 0.5, 1, and 2 g and twice at 1 g. The efficacy ratio was predicted from the TAM thus obtained.
Because the time course of serum concentration of CTRX in adult subjects was fitted to a 2-compartment model and both body weight and age were not incorporated as the covariate, the dosing method by which a fixed amount of CTRX is administered to patients has been thought to be adequate. Based on the efficacy ratio estimated from the MIC of CTRX, we have predicted that the once-a-day administration of CTRX even at 0.5g is effective on various infecting organisms.
采用群体药代动力学分析方法,根据2004年头孢曲松(CTRX)在日本成年人中的药代动力学以及感染病原体对CTRX的敏感性,预测CTRX的疗效。此外,我们还阐明了每日一次给药和每日两次给药在疗效上的差异。
群体药代动力学分析基于NONMEM已发表的CTRX血清浓度。使用一个纳入CTRX特定蛋白结合率变化的模型,研究体重和年龄对CTRX药代动力学的可能影响。基于该分析获得的群体药代动力学参数进行蒙特卡洛模拟,从而根据单次给予0.5、1和2 g以及两次给予1 g的CTRX的MIC值确定高于MIC的时间(TAM)。从由此获得的TAM预测疗效比。
由于成年受试者中CTRX血清浓度的时间过程符合二室模型,且体重和年龄均未作为协变量纳入,因此一直认为向患者给予固定量CTRX的给药方法是合适的。根据从CTRX的MIC估计的疗效比,我们预测即使每日一次给予0.5 g的CTRX对各种感染病原体也是有效的。